You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 17, 2024

VORAPAXAR SULFATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for vorapaxar sulfate and what is the scope of patent protection?

Vorapaxar sulfate is the generic ingredient in one branded drug marketed by Key Therap and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vorapaxar sulfate has one hundred and sixty-four patent family members in thirty-seven countries.

Summary for VORAPAXAR SULFATE
International Patents:164
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 1
Clinical Trials: 1
Patent Applications: 19
DailyMed Link:VORAPAXAR SULFATE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VORAPAXAR SULFATE
Generic Entry Date for VORAPAXAR SULFATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VORAPAXAR SULFATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ken MahaffeyPhase 2
Merck Sharp & Dohme Corp.Phase 2
Matthew MellPhase 2

See all VORAPAXAR SULFATE clinical trials

US Patents and Regulatory Information for VORAPAXAR SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Key Therap ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Key Therap ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VORAPAXAR SULFATE

Country Patent Number Title Estimated Expiration
Hong Kong 1129893 TRICYCLIC THROMBIN RECEPTOR ANTAGONIST ⤷  Sign Up
South Korea 100604742 ⤷  Sign Up
Australia 6690001 Thrombin receptor antagonists ⤷  Sign Up
Japan 2007056043 THROMBIN RECEPTOR ANTAGONIST ⤷  Sign Up
New Zealand 523075 Thrombin receptor antagonists ⤷  Sign Up
Taiwan I331608 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VORAPAXAR SULFATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1495018 2015C/037 Belgium ⤷  Sign Up PRODUCT NAME: VORAPAXAR, OU SON SEL OU SOLVAT PHARMACOLOGIQUEMENT ADMISSIBLE; AUTHORISATION NUMBER AND DATE: EU/1/14/976/001
1495018 SPC/GB15/039 United Kingdom ⤷  Sign Up PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/14/976/001 20150121; UK EU/1/14/976/002 20150121; UK EU/1/14/976/003 20150121; UK EU/1/14/976/004 20150121; UK EU/1/14/976/005 20150121; UK EU/1/14/976/006 20150121
1495018 CA 2015 00037 Denmark ⤷  Sign Up PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119
1495018 218 50011-2015 Slovakia ⤷  Sign Up PRODUCT NAME: VORAPAXARIUMSULFAT; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150121
1495018 PA2015027 Lithuania ⤷  Sign Up PRODUCT NAME: VORAPAXARUM; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119
1495018 1590037-6 Sweden ⤷  Sign Up PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/14/976/001 20150121
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.